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ABSTRACT 
Background: Glanzmann Thrombasthenia (GT) is a rare autosomal disease. HPA (Human Platelet 
Alloantigen) is a surface polymorphic alloantigen of platelets. This study was intended to investigate and 
compare the polymorphism of HPA-1 and HPA-5 genes in two groups of GT patients, with and without 
resistance to platelet and recombinant factor VII therapy. 
Materials and Methods: This case control study was performed on GT patients (n=16) with resistance to 
platelet therapy and recombinant factor VII and control group of GT patients (n=16) without resistance to 
platelet therapy and recombinant factor VII. The consent form was completed by each patient. Gene 
polymorphisms of HPA-1 and HPA-5 were investigated using SSP-PCR, and the obtained data were analyzed 
using statistical software SPSS16.0.  
Results: The results indicated no significant relationship between the studied genes and their resistance to 
platelet therapy and recombinant factor VII. The frequencies of HPA-1 genotype a/a were 98% and 94% in 
patient and control groups, respectively. The frequency of allele b was found to be less than allele a. The value 
of this allele was 4% in patient group and 1% in control group. In addition, the HPA-5a/a (98%) was the most 
frequent alloantigen?? (check it) in both groups. Seven percent (7%) of the patients had the HPA-5a/b 
genotype, and the HPA-5b/b was found to be absent in these individuals. 
Conclusion: According to the results obtained, it could be concluded that these genes play no role in 
resistance to platelet therapy.  
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INTRODUCTION 
   Glanzmann Thrombasthenia (GT) is a rare 
autosomal disease, caused by reduction or defects 
in the activity of membrane αIIbβ3 integrin receptor 
or Glycoprotein (GP) complex IIb / IIIa with lack of 
platelet aggregation. This GP is an abundant platelet 
GP that plays a key role in coagulation. Both genes 
are located on the long arm of chromosome 
17(17q21-q23)(1-5). GT is a mild to severe bleeding 
disorder in the mucosal surfaces. The clinical 
symptoms of the homozygous patients are 
petechiae, purpura, ecchymosis, menorrhagia, 
epistaxis, gingival bleeding, etc; however, it is often 
possible that the heterozygous patients shows no 
clinical symptoms3-4, 6.  
GT is classified into three types based on the 
expressed platelet GPIIb/ IIIa levels2. 
Therapy involves both preventive measures and 
treatment of specific bleeding episodes. Platelet 
transfusion and recombinant factor VII are 
important and standard treatments. But many 
patients show alloimmunization, especially after 
several platelet transfusions, which can cause 
serious side effects such as excessive bleeding 
during surgery, delivery or even tooth extraction 
without taking Precautions3,12. By finding the 
relationship between some alloantigens like HPA-1, 
HPA-5 gene polymorphisms and therapy refractory, 
patients can be properly cured by using platelets 
matched via HPA-1,5 without the occurrence of 
alloimmunizations. 
 HPA (Human Platelet Alloantigen) is a surface 
polymorphic alloantigen of platelets. Alloantibody is 
produced in patients who frequently receive 
platelet and it leads to resistance of treatment. 
HPA-1 is the most important platelet alloantigen 
system that is expressed in GPIIIa and the antibody 
against HPA-1 is commonly used in clinical 
laboratories3. 
HPA-5 is expressed in GPIa. There are a few studies 
on GT in Iran. The prevalence of this disorder is 
significant in southeast of Iran because of the high 
rate of consanguineous marriages1. This study was 
intended to investigate and compare the 
polymorphisms of the HPA-1 and HPA-5 genes in 
two groups of GT patients, those with and without 
resistance to platelet therapy and recombinant 
factor VII. 
MATERIAL AND METHODS 
Study population 
The case control study was performed during 2014 
to 2015 at Imam Khomeini hospital in Sistan & 
Balouchestan province, southeast of Iran. They 
were 16 GT patients who were resistant to platelet 
therapy and recombinant factor VII and the control 
group consisted of 16 GT patients without 
resistance to platelet therapy and recombinant 
factor VII. The consent form was completed by each 
patient. All demographic data, including age, 
parental consanguinity, clinical manifestations and 
family history were extracted from patients´ 
records. Each patient in control group was matched 
with case group. 
 
 DNA Extraction 
Genomic DNA was extracted from each patient’s 
blood using DNA extraction kit (Viogene). The 
quality of obtained DNA was evaluated by agarose 
gel electrophoresis containing 0.5 g/ml Ethidium 
bromide.  
Polymerase chain reaction (PCR) 
The primers of HPA-1 and HPA-5 gene 
polymorphisms are shown in Table1. PCR procedure 
was performed under standard conditions as shown 
in Table 2. The products were then separated on an 
agar gel Electrophoresis. The images of the gene’s 
PCR products are shown in Figures 1-4.   
 
Table 1. Primers for HPA-1 and HPA-5 gene polymorphisms 
Base pair primer sequences position 
90 1a: TCACAGCGAGGTGAGGCCA 
1b: TCACAGCGAGGTGAGGCCG 
Common primer: GGAGGTAGAGAGTCGCCATAG 
HPA-1 
246 5a: AGTCTACCTGTTTACTATCAAAG 
5b: AGTCTACCTGTTTACTATCAAAA 
Common primer: CTCTCATGGAAAATGGCAGTG 
HPA-5 
 
 
Table 2. PCR condition for HPA-1 and HPA-5 gene polymorphisms 
Cycles Temperature Time 
  First Denaturing 94 0C 5 min 
 Denaturing 94 0C 45sec 
30 
Cycles 
Annealing 600C 30Sec 
 Extension 720C 30 Sec 
 Final Extension  720C 5 min 
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Figure 1: The PCR products of the HPA-1 gene of patients by DNA 
Ladder 100 bp on the agar gel 
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Figure 2: The PCR products of the HPA-5 gene of controls by DNA 
Ladder 100 bp on the agar gel 
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Figure 3: The PCR products of the HPA-5 gene of patients by DNA 
Ladder 100 bp on the agar gel 
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Figure 4: The PCR products of the HPA-1 gene of controls by DNA 
Ladder 100 bp on the agar gel 
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PCR-Sequencing 
 The PCR products after purification were sent to 
Pishgam Company for sequencing, and then it was 
analyzed by the Chromas software.   
 
Statistical analysis 
All obtained results were reported as mean ± 
standard deviation (SD) and percentages. HPA-1 
and HPA-5 gene polymorphisms were finally 
compared in case and control groups. 
 
RESULTS 
   The age and sex of Glanzmann Thrombasthenia 
patients with resistance to treatment were 
matched with the control group. All patients were 
from a same geographical area to avoid 
environmental impacts. The average age of 
participants was 22.066 (standard deviation=7.66). 
The mean age of Glanzmann Thrombasthenia 
patients with resistance to platelet therapy and 
recombinant factor VII was 20.62 years and within 
the range of 9-32 years old; but the mean age of 
control group was 21.5 years and within the range 
of 3-39 years. The sex frequency distribution of the 
subjects in the control and patient groups is shown 
in Figure 5.  
 
Figure 5: Distribution of sex frequency of studied individuals in patients 
with resistance to platelet treatment and recombinant factor VII and 
the control group 
 
Genotype and allele frequencies 
The Genotype and allele frequencies of the HPA 
gene were performed using PCR method and 
sequencing. The results of genotype and allele 
frequencies are shown in Table 3. It is clear that the 
genotype frequency of HPA-1a/a in both groups of 
patients and controls is high. In addition, although 
the frequency of allele HPA-1 b in patients is high, 
there is no statistically significant difference. Fig 3 
also clarifies the Genotype frequencies of HPA-5a/a 
among Glanzmann Thrombasthenia patients. 
Frequency percentages were 93.5% and 100% for 
treatment-resistant patients and the control group, 
respectively.  
 
Table 3. The Genotype and allele frequency of the HPA-1 and HPA-5 in 
patients and control group 
HPA 
type 
Genotype and Allele 
frequency 
Both 
group 
N=32 
Control 
 
Refractory 
patient 
 
HPA-1 
1a/a 96% 98% 94% 
1a/b 4% 2% 6% 
1a 0.98 0.99 0.96 
1b 0.02 0.01 0.04 
HPA-5 
5a/a 96.5% 100% 0.93% 
5a/b 3.5% 0 7% 
5a 0.99 1.0 0.97 
5b 0.01 0.0 0.03 
  
DISCUSSION 
   In the present work, the frequency of the 
polymorphisms HPA-1 and HPA-5 in Glanzmann 
Thrombasthenia patients and the control group 
were examined and compared. This study was 
conducted on a total of 16 patients and 16 controls. 
The frequencies of HPA-1 genotype a/a were 98% 
and 94% in the patient and control group, 
respectively. These results are in accordance with 
the results of Madani et al. study, which involved 
the use of blood samples of blood donors. Also, 
HPA-1b/b genotype was not reported in the above-
mentioned study, which also agrees with our 
study’s results. Furthermore, the results of the 
genotypes of HPA-1a/b (96:4) obtained in the 
present work are comparable with the results of 
other studies  conducted in Saudi Arabia (100: 0), 
China (99.4:0.6), Korea (99:1) and India (100:0)7. 
The result of this study is also consistent with the 
result of Tan (2012), which was conducted in 
Malaysia. In his study, the frequent HPA was 
reported to be the variant HPA-1a/a, and allele b 
was found to be of low frequency which are similar 
to the findings of our study5. The frequency of allele 
b was found to be less than allele a. The value of 
this allele was 4% in patients and 1% in control 
group. This value is higher for patients than the 
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range of Asian Allele b, but it was not statistically 
significant.  Although this result is high compared 
with the Asian value, it is however low compared 
with the amount of allele b among the European 
population. It should be noted that the present 
study was a comparative study conducted on 
healthy and patient groups, while the other studies 
were conducted on only healthy people. In this 
current study, the significant relationship between 
polymorphisms HPA-1 and resistance to platelet 
therapy and recombinant factor VII were not found 
in both patients and healthy Individuals which is in 
agreement with Tanboga (2013) study that was 
conducted on coronary artery patients. No 
relationship was observed by Tanboğa on 
angiography between patients receiving clopidogrel 
and polymorphisms HPA-1. Therefore,  they 
concluded that HPA-1 gene polymorphism is not 
associated with  platelet aggregation or resistance 
to clopidogrel8. However, the results of this study 
are not compatible with the results of Soundravally 
et al (2007). They conducted a study on patients 
with hemorrhagic fevers and detected no significant 
relationship between the HPA-1 heterozygous 
genotype and the incidence of hemorrhagic fevers. 
The heterozygous individuals are highly susceptible 
to the disease, while the people with genotype 
HPA1a/1b are highly at risk of dengue shock 
syndrome9. The investigation of HPA-5 frequency 
showed the HPA-5a/a as the most frequent 
genotype in both study groups. It was observed in 
the entire control group, while 7% of the patients 
had the HPA-5a/b genotype and the HPA-5b/b was 
absent in the individuals. The frequency of the allele 
b was observed in 3% of the patient group, and it 
was not detected in the control group.  Madani et 
al. also had a 98% frequency of HPA-5a/a in blood 
donors7. Shayegan et al. conducted a study in 
Tehran in 2011. They found HPA-5 a/a (99%) as the 
most frequent HPA-5 genotype; it was seen in the 
control group and was 90.5% in the patient group. 
This confirms the finding of this present study.  
Shaygan et al. found HPA-5b frequency of 1% in 
both patient and control groups. However, in our 
study, the frequency of allele b in patient group was 
found to be high compared with the control group. 
Although 3% of the patients had the HPA-5b, this 
allele was not detected in the control group6. In this 
present study, the genes of HPA-1 and HPA-5 were 
not seen in the homozygous allele b, which was 
consistent with Shayegan et al. study. Also, this has  
not been reported by other studies6, 10-11. 
 
CONCLUSION 
   This study aimed to investigate the gene 
polymorphisms of HPA-1 and HPA-5 in Glanzmann 
Thrombasthenia patients with resistance to platelet 
therapy and recombinant factor VII compared with 
the control group in Southeast of Iran. It was 
observed that there was no relationship between 
the alleles, genotype of these two genes, and the 
resistance to platelet therapy and recombinant 
factor VII. This may point out to the possible 
involvement of other genes in resistance 
phenomenon, thus other alloantigen should be 
investigated. This is the first report in the context of 
resistance to platelet therapy in Glanzmann 
Thrombasthenia patients and the obtained data can 
be used as basic data for other studies since 
epidemiogenetic recognition is considered as one of 
the important principle in diagnostic and 
therapeutic planning.  
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